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 20 
Abstract 21 
The herpes simplex virus type 1 (HSV-1) is widespread in the population and in most cases its 22 
infection is asymptomatic. The currently available anti-HSV-1 drugs are acyclovir and its 23 
derivatives, although long-term therapy with these agents can lead to drug resistance. Thus, the 24 
discovery of novel anti-herpetic compounds deserves additional effort. Naturally occurring 25 
antimicrobial peptides (AMPs) represent an interesting class of molecules with potential antiviral 26 
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properties. To the best of our knowledge this work is the first demonstration of the in vitro anti-27 
HSV-1 activity of Temporin B (TB), a short membrane-active amphibian AMP. In particular, when 28 
HSV-1 was pre-incubated with 20 g/ml TB, significant antiviral activity (5 log reduction of viral 29 
titer) was observed. Such an effect was due to the disruption of the viral envelope, as demonstrated 30 
by transmission electron microscopy. Moreover, TB partially affected different stages of HSV-1 life 31 
cycle, including the attachment, the entry of the virus into the host cell as well as the following post 32 
infection phase. Furthermore, its efficacy was confirmed on human epithelial cells, thus suggesting 33 
TB as a novel approach for the prevention and/or treatment of HSV-1 infections.  34 
 35 
Introduction 36 
One of the most widespread human pathogens is the herpes simplex virus type 1 (HSV-1), an 37 
enveloped DNA virus whose primary infection generally occurs in the oropharyngeal mucosa, 38 
followed by neuronal latency in the peripheral ganglia. Reactivation of the latent results either in 39 
asymptomatic virus shedding or recurrent herpes disease (1-3). In most cases HSV-1 infection is 40 
asymptomatic, and the majority of people are unaware of their HSV-1-status. However, in 41 
immunocompromised individuals, HSV-1 recurrences are associated with severe symptoms and 42 
rarely, continuous virus reactivations can be the beginning of more serious complications, such as 43 
encephalitis and keratitis (4). HSV-1 infections are usually treated with antiviral agents such as 44 
acyclovir and its derivatives; unfortunately, these therapies neither prevent recurrence arising from 45 
the reactivation of the latent virus nor do they completely eliminate the virus (5). Among 46 
immunocompetent patients, HSV-1 infection is controlled rapidly by the human host's immune 47 
system, thus requiring short-term antiviral therapy with minimal risk of developing resistance. In 48 
contrast, immunocompromised patients may be unable to control HSV-1 infection and generally 49 
need long-term anti-herpetic therapy which is more likely to induce drug resistance (6, 7). In this 50 
context, it is essential to develop novel anti-HSV-1 agents.  51 
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Recently, naturally occurring antimicrobial peptides (AMPs) have been studied for their potential 52 
antiviral properties, as demonstrated against several viruses (8-11). AMPs are expressed in 53 
almost all living organisms including plants and animals, as conserved products of innate 54 
immunity (12). Frog-skin is one of the richest sources of AMPs that are synthesized by 55 
adrenergically innervated dermal glands and stored within granules that are released onto the skin 56 
surface by a holocrine mechanism in response to alarm or injury (13, 14). A family of amphibian 57 
AMPs, originally isolated from the european red frog Rana temporaria, are called temporins. 58 
These peptides represent the shortest AMPs found in nature to date with a typical length of 10-13 59 
amino acids and a conserved sequence (15, 16). They are amidated at the C-terminus and are 60 
characterized by a weak cationic charge (net charge ranging from +2 to +3) owing to the presence 61 
of only 1 or 2 positively-charged amino acids, such as lysine or arginine, in their sequence.  62 
Temporins, like other AMPs, exert antimicrobial activity against bacteria and mycetes (17, 18), 63 
while their antiviral activity has been reported only against a few enveloped or non-enveloped 64 
viruses of ectothermic animals (19). Furthermore, no studies regarding the activity of temporins 65 
against human viruses have been reported to date. 66 
Here we demonstrate for the first time the in vitro antiviral activity of temporin B (TB) against 67 
HSV-1. When added to HSV-1-infected cells, TB significantly reduced viral titer, but more 68 
importantly the highest inhibition was obtained by pre-incubation of HSV-1 with the peptide for 69 
1 hr at 37 °C, thus demonstrating its virucidal activity.  70 
 71 
Materials and Methods 72 
Peptide. Synthetic TB, LLPIVGNLLKSLL-NH2, was supplied in a purity >98% by Selleck 73 
Chemicals (Houston, TX, USA), as previously reported (20). Briefly, the peptide was synthesized 74 
by standard Fmoc methodology and purified by RP-HPLC on a semipreparative C18-bonded silica 75 
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column (Kromasyl, 5 μm, 100 Å, 25 cm × 4.6 mm) using a gradient of acetonitrile in 0.1 % aqueous 76 
trifluoroacetic acid at a flow rate of 1.0 ml/min.  77 
 78 
Cell culture and virus production 79 
African green monkey (Vero) cells were grown in RPMI 1640 medium supplemented with 10% 80 
heat-inactivated fetal bovine serum (FBS), 0.3 mg/ml L-glutamine, 100 U/ml penicillin and 100 81 
µg/ml streptomycin, at 37 °C in an atmosphere of 5% of CO2. Human embryonic kidney (HEK-82 
293) cells and human cervix epithelial (HeLa S3) cells were grown in Dulbecco’s modified Eagle’s 83 
medium (DMEM) supplemented with 10% FBS, 0.3 mg/ml L-glutamine, 100 U/ml penicillin and 84 
100 µg/ml streptomycin. All reagents were purchased from Sigma Aldrich. Virus production was 85 
performed as previously reported (21). Briefly, monolayers of Vero cells in 75-cm
2 
tissue culture 86 
flasks were infected with HSV-1 (strain F) at a multiplicity of infection (m.o.i.) of 0.01. After 48 87 
hrs at 37 °C, the needed time to observe the virus-induced cytopathic effect, infected cells were 88 
harvested with 3 freeze-and-thaw cycles, cellular debris were removed with low-speed 89 
centrifugation for 10 minutes, and virus titer was measured on the supernatants by standard plaque 90 
assay, as described below. The titer of the virus preparation was 5 x 10
8 
plaque forming units 91 
(pfu)/ml. The virus was stored at – 80 °C until used. 92 
 93 
Cellular toxicity assays 94 
Cellular toxicity of TB was evaluated by Trypan blue (0.02% final concentration) exclusion assay 95 
(22). Viability and growth of Vero, HEK-293 and HeLa S3 cells were tested in vitro by MTT [3-(4, 96 
5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide] assay, as previously reported (23, 24). 97 
Briefly, cellular monolayers were incubated with TB at concentrations of 1, 10, 20, 50, 75 and 100 98 
µg/ml (corresponding to 0.72, 7.2, 14.4, 36, 54, 72 M, respectively) in culture medium for 24 hrs; 99 
the medium was replaced with 50 µl of 1 mg/ml solution of MTT in RPMI or DMEM without 100 
phenol red (Sigma-Aldrich). Cells were incubated at 37 °C for 3 hrs, and then 100 µl of acidified-101 
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isopropanol (HCl 0.1N in isopropanol) was added to each well. After a few minutes at room 102 
temperature to ensure that all crystals were dissolved, the plates were read using an automatic plate 103 
reader with 550 nm test wavelength and a 690 nm reference wavelength. CC50, defined as the drug 104 
concentration required for reducing the cell viability by 50%, was calculated by regression analysis 105 
of the dose–response curve generated from the data. 106 
 107 
In vitro HSV-1 Infection  108 
Vero, Hela S3 and HEK-293 cells were seeded in 24-well plates at a density of 1.5 x 10
5 
cells/ml 109 
and infected with HSV-1 at 1 m.o.i. After incubation for 1 hr at 37 °C to allow virus adsorption to 110 
the host cells (adsorption phase), the medium was removed and replaced with fresh medium 111 
supplemented with 2% FBS and the plates were maintained for 24 hrs at 37 °C in an atmosphere of 112 
5% CO2  (post infection phase).  113 
 114 
Determination of viral yields 115 
The viral titer was measured through the standard plaque assay, as previously described (25, 26). 116 
Briefly, supernatants of infected samples were used at different dilutions to infect monolayers of 117 
Vero cells. After 1 hr at 37 °C, the monolayers were washed, the medium was replaced with RPMI 118 
containing 2% carboxymethylcellulose (CMC) and 2% FBS and the plates were maintained at 37 119 
°C for 48-72 hrs until plaques formation. Thus, the CMC solution was removed, the monolayers 120 
were fixed with cold methanol for 20 minutes at -20 °C, washed with PBS and stained with a 0.5% 121 
crystal violet solution. The plaques were counted and the viral titer calculated as PFU/ml. 122 
To assay antiviral activity, plaque reduction assay was performed as previously described, with 123 
some modification (27). Vero cells were seeded in 24-well plates at a density of 1.5×10
5
 cells/well. 124 
Next day, confluent cell monolayers were infected with HSV-1 at 1 m.o.i. for 1 hr at 37 °C. The 125 
unabsorbed virus was subsequently removed by washing the cells three times with PBS and the 126 
medium replaced with RPMI 1640 containing 1% CMC, 2% FBS and different concentrations of 127 
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TB. After further incubation at 37 °C for 36/48 hrs, cells were fixed with cold methanol, stained 128 
with 0.5% crystal violet solution and viral plaques were counted. The concentration producing 50% 129 
reduction in plaque formation (IC50) was determined by regression analysis using Graph Pad Prism 130 
version 6.0 software by fitting a variable slope-sigmoidal dose–response curve. 131 
 132 
Pre-treatment Assay 133 
Vero cells were incubated with 20 µg/ml TB for 3 hrs at 37 °C, then washed with PBS and infected 134 
with HSV-1 at 1 m.o.i. for 24 hrs. Thus, the supernatant of infected cells was used to determine 135 
viral titer by standard plaque assay. 136 
 137 
Time-of-addition assay  138 
TB (20 μg/ml) was added to a confluent monolayer of Vero cells infected with HSV-1 (1 m.o.i.) at 139 
different times of infection, as follows: (i) only during viral adsorption period (1 hr, 37 °C); (ii) 140 
immediately after the adsorption period and maintained for the following 24 hrs; (iii) during viral 141 
adsorption period (1 hr, 37 °C) and immediately after adsorption period for the following 24 hrs. 142 
HSV-1 infected HEK-293 and HeLa S3 cells were treated with TB (20 μg/ml) during viral 143 
adsorption period (1 hr, 37 °C) or immediately after the adsorption period and maintained for the 144 
following 24 hrs. The supernatants from infected cells were used to determine virus titer by 145 
standard plaque assay, as described above.  146 
 147 
Attachment Assay 148 
The attachment assay was performed as previously described (28) with some modifications. Briefly, 149 
Vero cells were incubated with a combination of TB and HSV-1 (1 m.o.i.) for 1 hr at 4 °C. Then 150 
cells were washed twice with PBS to remove both unattached virus and peptide, and maintained for 151 
1 hr at 37 °C in RPMI (adsorption phase). Cells were then washed three times with PBS and 152 
incubated for 36 hrs at 37 °C with RPMI 1640 containing 1% CMC and 2% FBS to perform the 153 
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plaque reduction assay. Monolayers were then fixed with cold methanol, stained with 0.5% crystal 154 
violet solution, and plaques were counted to determine the viral titer. 155 
 156 
Entry Assay 157 
The entry assay was performed as previously reported (29) with some modifications. Briefly, 158 
confluent monolayers of Vero cells were infected with HSV-1 at 1 m.o.i. for 1 hr at 4 °C. Then, the 159 
cells were incubated at higher temperature (37 °C) to maximize the penetration of virus in the 160 
presence or absence of TB. After 1 hr, the supernatants were removed and cells were treated with 161 
PBS, pH 3 for 1 min to neutralize any remaining attached virus. After four washes with serum-free 162 
RPMI 1640, cells were overlaid with medium containing 1% CMC and 2% FBS and incubated at 163 
37 °C for 36 hrs to perform a plaque reduction assay. Monolayers were then fixed with cold 164 
methanol and stained with crystal violet solution, and plaques were counted to determine the viral 165 
titer. 166 
 167 
Cell to cell spread assay 168 
The cell to cell spreading of HSV-1 assay was performed as previously reported (30, 31) with some 169 
modifications. Briefly, Vero cells were seeded in 96 wells and infected with HSV-1 at 0.1 m.o.i. for 170 
1 hr at 37°C, in the presence of TB (20 g/ml, first dose). Cellular monolayers were washed and 171 
medium replaced with fresh medium containing TB (20 g/ml, second dose) and 10 g/ml anti-172 
HSV-1 antibody (AbD Serotec) to neutralize HSV-1 particles released from infected cells and to 173 
ensure that HSV-1 infection was actually due to cell-to-cell virus spread. As controls, Vero cells 174 
were infected with HSV-1 and treated or no with neutralizing HSV-1 antibody or with TB. Twenty-175 
four hrs p.i. cells were fixed with 4% paraformaldehyde in PBS for 15 min and permeabilized in 176 
0.1% triton X-100 PBS for 5 min at room temperature (rt). Following the incubation with Odyssey 177 
Blocking Buffer for 1 hr at rt, cells were incubated with mouse anti-gB (Santa Cruz, 1:1000 dilution 178 
in Odyssey Blocking buffer) for 1 hr at rt. After three washings, cells were incubated with labeled 179 
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secondary antibody IRDye 800 CW Goat Anti Mouse (LI-COR Biosciences, 1:1000 dilution in 180 
Odyssey Blocking buffer) for 1 hr at rt (26). Finally, the plate was scanned on the LI-COR Odyssey 181 
Infrared Imaging System, and the relative fluorescence intensity value of each well was read by LI-182 
COR Image Studio Software developed for Odyssey analysis. The obtained images represented foci 183 
of HSV-1 infection (green).  184 
 185 
HSV-1/Temporin pre-incubation  186 
 TB (20 μg/ml) was pre-incubated with HSV-1 (1 m.o.i.) at 37 °C for 1 hr, and the mixture was 187 
used to infect cellular monolayers. After viral adsorption for 1 hr at 37 °C, the plates were washed 188 
and the medium replaced with fresh medium containing 1% CMC and 2% FBS for 36 hrs at 37 °C. 189 
The viral titer was evaluated as already described.  190 
 191 
Western blot analysis 192 
Vero infected cells, treated or not with TB, were washed with PBS, recovered and centrifuged at 193 
770 x g for 10 min; the pellet was suspended in cold lysis buffer (10 mM Tris-HCl, 150 mM NaCl, 194 
1 mM phenylmethylsulfonyl fluoride (PMSF), phosphatase inhibitor mixture, 1% Triton X-100, pH 195 
7.4; Sigma Aldrich) and incubated on ice for 30 min. After centrifugation (10,000 x g for 30 min) 196 
the supernatants were collected and assayed to determine protein concentration (Bradford method, 197 
Bio-Rad). Equivalent amounts of proteins were suspended in SDS sample buffer containing 100 198 
mM 1,4-Dithiothreitol (Sigma Aldrich), boiled at 100 °C for 10 minutes and then separated with 199 
SDS-PAGE, and blotted onto nitrocellulose membranes for Western blot assay. The membranes 200 
were blocked with 10% nonfat dry milk (Biorad) in TBS-Tween 0.1% for 1 h at room temperature. 201 
Primary antibodies [anti-Herpes simplex virus 1/2 (AbD Serotec), that raises against ICPs and late 202 
structural viral proteins, and anti-glycoprotein B (Santa Cruz Biotecnology)] were added at a final 203 
concentration of 1 μg/ml and maintained overnight at 4 °C. Secondary antibodies were horseradish 204 
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peroxidase-conjugated (Jackson ImmunoResearch). Blots were developed with ECL-Plus Detection 205 
System (Thermo Scientific) and subjected to densitometric scanning. 206 
 207 
Transmission electron microscopy 208 
Transmission electron microscopy (TEM) analysis was performed as described by Bultmann et al. 209 
(32) with some modifications. Briefly, for negative staining, a 10 µl drop of HSV-1 (1x10
6
 or 5x10
6 210 
pfu) containing TB or TA suspension, previously incubated at 37 °C for 1 hr, was placed on a 211 
carbon-coated grid for 30 seconds. Subsequently, the grid was washed with several droplets of 212 
phosphotungstic acid solution (2% w/v, pH 6.8). The last droplet of staining solution was left for 10 213 
seconds and then blotted with filter paper. Afterwards, the grid was allowed to air dry before 214 
examination. For each condition, several grids were examined using a Philips CM 100 transmission 215 
electron microscope at an accelerating voltage of 100 kV (Microscopy Center, University of 216 
L’Aquila, Italy). A total number of 90 viral particles was examined. 217 
 218 
Statistical analysis 219 
Unpaired data were analyzed with the Student’s t test, and P values < 0.05 were considered 220 
significant. Data are presented as means ± standard deviations (SD). 221 
 222 
Results 223 
Temporin B is not cytotoxic and reduces HSV-1 titer  224 
In a first set of experiments, we evaluated the effect of TB on Vero cell viability. To this aim, cells 225 
treated with different concentrations (1-100 µg/ml) of peptide for 24 hrs were stained with Trypan 226 
blue; their microscopic examination revealed no significant mortality in cells treated with the 227 
peptide at a concentration up to 40 µg/ml. On the contrary, at higher concentrations, morphological 228 
alterations, loss of cell viability and modification of cell multiplication rate were observed (data not 229 
shown). These results were confirmed by means of MTT-based assay. As shown in Fig. 1A, cell 230 
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proliferation was not affected by TB at low doses, whereas it decreased in a dose dependent manner 231 
starting from 50 μg/ml. The 50% cytotoxic value (CC50) for the peptide was 90.4 µg/ml. On the 232 
basis of these results, in order to evaluate the potential antiviral activity of TB against herpes 233 
simplex virus type 1 (HSV-1), we used the peptide at concentrations ranging from 0.1 to 40 μg/ml. 234 
To this aim, a plaque reduction assay was performed. The results, shown in Fig. 1B, indicate that 235 
TB reduced HSV-1 titer in a dose-dependent-trend. IC50 was 2.507 g/ml [95% confidence = 2.325 236 
to 2.703; Selectivity Index (CC50/IC50) = 36.06]. On the basis of the obtained results, the next 237 
experiments were performed using TB at 20 µg/ml.  238 
 239 
TB affects life cycle and cell to cell spreading of HSV-1  240 
In order to evaluate the effect of TB on HSV-1 life cycle, Vero cells were infected with HSV-1 and 241 
incubated with TB at different times as follows: during the viral adsorption (1 hr, ads); immediately 242 
after viral adsorption (for 24 hrs, post); during viral adsorption and for the following 24 hrs (ads + 243 
post). The results showed that TB was effective in reducing HSV-1 titer of about 1.5 log in all the 244 
experimental conditions tested (Fig. 2, upper panel). These results were confirmed through the 245 
analysis of ICPs and late structural viral proteins, among which gB. As shown in Fig. 2, lower 246 
panel, viral protein content was reduced in TB-treated cells at any condition with respect to 247 
untreated infected cells. Interestingly, the highest inhibition was obtained when the peptide was 248 
added as double doses (ads+post), as confirmed by densitometric analysis of gB (about 2.5 fold 249 
reduction).  250 
On the basis of these results, we evaluated the effect of TB on HSV-1 cell to cell spread. Indeed, it 251 
is known that gB, gD, gH, and gL are the principal HSV-1 glycoproteins required for virus entry 252 
into the cell and for cell-to-cell spread (33). To this aim, confluent monolayer of Vero cells were 253 
treated or not with TB during viral adsorption and for the following 24 hrs of infection. Moreover, 254 
some samples were also incubated with HSV-1 neutralizing antibody to ensure that the occurred 255 
HSV-1 infection was due to cell-to-cell spread. Immunostaining analysis by LI-COR Odyssey 256 
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Infrared Imaging System (Fig. 3), revealed that neutralizing antibody and TB were able to reduce 257 
foci of infection of about 20% and 50% respectively, compared to untreated infected cells. 258 
Importantly, in the presence of both antibody and TB the inhibition was higher with respect to that 259 
obtained by single treatment (about 65%; **P < 0.001 vs. untreated infected cells), thus suggesting 260 
that TB may prevent cell to cell spreading of HSV-1. 261 
  262 
TB inhibits the attachment of the virus to host cell 263 
Next we investigated the antiviral activity of TB during the very early phases of HSV-1 life cycle, 264 
i.e. attachment and penetration phases. To this aim, two different tests were performed: a) the 265 
attachment assay, during which the virus can only bind the surface of the host cells but does not 266 
enter the cell, in the presence or absence of TB; b) the entry assay, during which the peptide was 267 
added immediately after virus attachment to assess its ability to prevent entry. As shown in Fig. 4A, 268 
HSV-1 titer was significantly reduced by about 2 log and 1 log in the attachment and entry assays, 269 
respectively. To confirm that the anti herpetic efficacy of TB was greater during the attachment 270 
phase of virus life cycle and to exclude the possibility that TB could alter the binding of the virus to 271 
the host cell by interfering with some receptors on the cell surface, cell monolayers were pretreated 272 
with the peptide for 3 hrs at 37 °C before HSV-1 infection. Supernatants of infected cells were 273 
recovered 24 hrs after infection and used for standard plaque assay. No difference in viral 274 
replication between untreated and TB-pretreated cells was observed (Fig. 4B), thus suggesting that 275 
TB does not exert any activity on the host cell surface.  276 
 277 
TB possesses virucidal properties 278 
In order to verify the potentially direct effect of TB on virions, HSV-1 was pre-incubated with TB 279 
(HSV-1+TB) or no TB (HSV-1) for 1 hr at 37 °C and then the mixtures were used to infect the 280 
cells. Immediately after viral adsorption, cells were washed and incubated for the following 24 hrs 281 
with fresh medium. The supernatant of infected cells was used to perform standard plaque assay, 282 
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while cell monolayer was harvested and subjected to western blot analysis of viral proteins. 283 
Surprisingly, the plaques count showed that TB reduced by 5 log the HSV-1 titer compared to 284 
untreated infected cells (Fig. 5A, below the gel). This strong reduction corresponds to 99.99% 285 
inhibition of HSV-1 replication, thus suggesting that TB acts directly on viral particles. These data 286 
were also confirmed from the almost complete absence of viral proteins in HSV-1+TB samples 287 
compared to those of HSV-1 (Fig. 5A). 288 
To confirm the direct effect of TB on HSV-1 particles, high m.o.i. of HSV-1 (20 fold higher than 289 
standard conditions, i.e. 20 m.o.i) were pre-incubated with 20 μg/ml TB at 37 °C for 1 hr. The 290 
mixture was then diluted to 1 m.o.i. and used to infect cells. After viral adsorption, cells were 291 
incubated with fresh medium supplemented with CMC and plaque reduction assay was performed. 292 
As shown in Fig. 5B, although in this assay the TB:HSV-1 ratio was altered compared to standard 293 
experimental procedures, the peptide was able to significantly reduce plaque formation (more than 294 
2 log inhibition). These results support a direct effect of TB on HSV-1 particles, probably due to its 295 
interaction with some components of the viral envelope and/or to disruption of the external viral 296 
layer (virucidal effect). 297 
To verify this hypothesis we decided to study the morphology of virus particles (incubated or not 298 
with TB) by transmission electron microscopy (TEM). In Fig. 6A (panel a), the image of HSV-1 is 299 
reported. All viral components (envelope, tegument and nucleocapsid) were clearly visible and 300 
intact. On the contrary, in TB-pretreated HSV-1 virions a loss of viral envelope integrity was 301 
revealed (Fig. 6A panels b, c) confirming the virucidal effect of TB on HSV-1 virions. Afterwards, 302 
to check whether such virucidal effect was an exclusive property of TB, we tested the activity of 303 
another member of the temporins family i.e. TA (FLPLIGRVLSGIL-NH2, from Selleck Chemicals, 304 
US) for comparison. Note that TA previously showed activity against different viruses (19). Like 305 
TB, also TA is a peptide with an alpha-helical structure in membrane mimicking environments, a 306 
net charge of +2 at neutral pH and a length of 13 amino acids (Fig. 6) (16). TA was able to interfere 307 
with HSV-1 replication when it was pre-incubated with the viral particles at 37 °C for 1 hr, but this 308 
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inhibition was lower than that of TB (1 log versus 5 log) (data not shown). Importantly, when the 309 
effect of TA on viral particles was visualized by electron microscopy, no disruption of the viral 310 
envelope was detected (Fig. 6A, panels d, e). Finally, to confirm whether TB was able to disrupt the 311 
envelope of the virus, we decided to incubate more viral particles with TB and quantified the 312 
virions that were broken by the peptide (Fig. 6B). Many TB-pretreated HSV-1 virions lost or 313 
showed a broken envelope (~88.8% ± 7.6 or ~8.2 % ± 5.3, respectively) while ~2.9% ± 2.3 were 314 
still intact (*P < 0.05). 315 
All these results strongly indicate that TB is effective in inhibiting viral replication by disrupting 316 
HSV-1 envelope. 317 
 318 
TB reduces HSV-1 titer in human epithelial cells 319 
On the basis of the obtained results, TB has emerged as a promising anti-HSV-1 agent. Thus, we 320 
tested its activity on two different human epithelial cells, HeLa S3 and HEK-293, already used for 321 
HSV-1 studies (34, 35). First, the potential cytotoxic effect of TB was evaluated by the MTT assay. 322 
As shown in Fig. 7A, no toxicity was observed at concentrations as high as 50 g/ml of TB. The 323 
IC50 was 93g/ml and 84 g/ml for HeLa S3 and HEK-293 cells, respectively. Then viral 324 
replication was assayed in presence or no of TB. The results demonstrated that TB was also 325 
effective in contrasting HSV-1 replication in both human epithelial cells (Fig. 7B). In particular, the 326 
peptide reduced plaque formation of about 2 log when was added during the adsorption phase. The 327 
strongest effect (about 5 log reduction) was found when the peptide was pre-incubated with HSV-1 328 
virions for 1 hr at 37 °C, thus confirming TB virucidal activity. 329 
 330 
Discussion  331 
In this paper we have demonstrated for the first time that the AMP TB exerts significant anti-HSV-332 
1 activity mainly through its direct virucidal properties.  333 
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Previous mechanistic studies regarding the antimicrobial effect of temporins against bacteria or 334 
fungi demonstrated that their activity is related to the disruption of the microbial membrane (36, 335 
37). Several authors have reported that certain defensins, cationic peptides which exert their 336 
antimicrobial activity through membrane permeabilization of the invading microorganism (38), also 337 
display antiviral activity against various enveloped DNA or RNA viruses, including HSV-1, HSV-338 
2, cytomegalovirus, vescicular stomatitis virus and influenza virus A/WSN (9, 39-42). However, 339 
these peptides are not able to inactivate two non-enveloped viruses, ECHO virus 11 and reovirus 340 
type 3. The same authors suggested that the defensins interact with the viral envelope, causing lipid 341 
bilayer perturbation (40). Also amphibian AMPs, such as dermaseptins, have been reported to 342 
inhibit HSV-1 and HSV-2 replication (43, 44). The mechanism of action seemed to be related to 343 
their characteristic cationic charge. Indeed, ionic interactions between the positively-charged amino 344 
acids present in the peptide sequence and the negatively-charged sulfate and carboxyl groups in 345 
heparan sulfate of cell surface proteoglycans -the cellular receptor for the viral B and C 346 
glycoproteins- could block the attachment of the virus to the host cell (44). With regards to the 347 
temporins, Chinchar et al. (19) showed the ability of the isoform A to inhibit channel catfish virus 348 
and frog virus 3 replication, although the mechanism of action remains to be determined. Here, we 349 
report that TB exhibited high anti-HSV-1 activity, particularly when pre-incubated alone with 350 
herpes virus particles prior to cell infection, thus causing disruption of the viral envelope, as 351 
observed by TEM analysis. In comparison, TA did not affect HSV-1 envelope integrity. The 352 
differences in primary structure position of the single basic residue (Arg7 in TA and Lys10 in TB, 353 
See Fig. 6) and hydrophobicity of the two peptides (16) are all factors that may account for the 354 
ability of TB to destroy the viral envelope in comparison to TA. This is in accordance with 355 
literature data showing a greater tendency for TB to destabilize both anionic and zwitterionic 356 
membranes (45). Note that viral envelope contains lipid rafts that have been reported to regulate 357 
surface charge and protein localization and to be responsible for the electrostatic interaction with 358 
cationic peptides (46, 47).  Importantly, while the mode of action of AMPs against bacterial cells 359 
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has already been well characterized and studied, their antiviral mechanism is not yet fully 360 
understood. Nevertheless, according to the proposed model of destabilization of influenza virus 361 
envelope, peptide molecules may insert into and disrupt the lipid bilayer following electrostatic 362 
interaction with the viral capside. This would then be followed by disruption of the viral envelope 363 
with leakage of viral components   (48).  364 
TB treatment also affected the attachment phase of HSV-1 cycle, but this inhibition was more 365 
modest with respect to TB-HSV-1 pre-incubation. The reason of this trend could be related to the 366 
weakly cationic nature of the peptide, due to the presence of only one basic residue (lysine) in its 367 
sequence. However, despite the weak cationic character, the interactions between the peptide and 368 
the host cell surface might partially affect the virus attachment to the host cell. When cell 369 
monolayers were pre-treated for 3 hrs with TB and then infected with HSV-1, no viral titer 370 
impairment was observed with respect to untreated cells thus indicating that the inhibitory activity 371 
of TB is not due to its interference with the cellular receptors. Interestingly, when TB was added 372 
during the viral adsorption phase, HSV-1 titer reduction was similar to that observed during the 373 
attachment assay, thus supporting the ability of the peptide to inhibit the very early stage of the viral 374 
multiplication cycle.  375 
Furthermore, in our study we also found out that administration of TB to the cells during the post 376 
infection phase was able to inhibit HSV-1 infection. TB-induced HSV-1 inhibition was more 377 
pronounced when two consecutive doses of the peptide, i.e. during viral adsorption and post 378 
infection phases were used. These data suggest that TB can also exert its antiviral activity by 379 
affecting one or more cellular targets that the virus exploits for promoting its life cycle. Indeed, it is 380 
known that HSV-1, like other viruses, manipulates host cell machinery and metabolism to its 381 
advantage (49-51). Some AMPs exert their antibacterial activity through additional targets 382 
regulating essential biochemical reactions, e.g. RNA, protein or DNA biosynthesis and/or inhibition 383 
of cytosolic enzymes (52). Accordingly, in our experimental system, when TB was added as double 384 
doses (ads+post), we observed a strong reduction of ICPs and late viral proteins expression, among 385 
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which gB. It is important to note that this glycoprotein, as well as others, is involved in cell to cell 386 
spread of HSV-1 (33), and we found that TB is able to prevent spreads from infected cells to 387 
neighboring uninfected cells. Therefore, we hypothesize that the peptide by impairing gB 388 
expression may interfere with HSV-1 spreading. 389 
Due to the multiplicity of targets, AMPs are considered less likely to induce resistance mechanisms 390 
in microbes than conventional drugs (53). Regarding HSV-1, the available antiviral drugs to fight 391 
the viral infections are acyclovir and its derivatives, but unfortunately, immunocompromised 392 
patients that require longer-term anti-HSV therapy can develop drug resistance (54). Thus, the 393 
search for new antiviral agents acting on both viral particles and cell pathways useful for the virus 394 
may control HSV-1 infection and bypass pharmacological resistance. In this scenario, TB can be 395 
considered as a promising preventive or therapeutic anti-herpetic agent, especially for topical usage. 396 
Noteworthy, recent technological breakthroughs have sharply raised the interest in the usage of 397 
peptides as efficacious and safe new therapeutics (52, 55). This is confirmed by the increasing 398 
number of antitumor and/or antiviral AMPs, which is expected to lead to a shake-up in their current 399 
scenario, moving from the clinical experimentation to the market (56). Thanks to advances in 400 
nanotechnologies, it is actually possible to conjugate peptides to nanocarriers with the aim to 401 
protect them from proteolytic degradation and to prolong their bioavailability (57). In addition, the 402 
development of nanoformulations has contributed to optimize peptides delivery to the target site 403 
(58-61). It is therefore conceivable the application of peptide-based drugs, mainly for topical 404 
treatment of infections.  405 
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FIGURE LEGENDS 412 
Figure 1 (A) Cytotoxic (CC50) and (B) antiviral (IC50) effect of TB on Vero cells. (A) Cellular 413 
monolayers were incubated with increasing concentration of the compound for 24 hrs and cell 414 
proliferation was determined by MTT assay. The 50% cytotoxic concentration (CC50) of TB was 415 
calculated by regression analysis of the dose–response curve. (B) HSV-1-infected cells were treated 416 
with the peptide at concentrations ranging from 0.1 to 40 μg/ml and viral titer inhibition was 417 
calculated by plaque reduction assay. The 50% inhibitory concentration (IC50) of the compound was 418 
calculated by regression analysis as described in Materials and Methods section.  419 
Each value is the means ± SD of three experiments, each performed in duplicate. 420 
Figure 2 TB reduces HSV-1 replication at different stages of virus life cycle. A time-of-addition-421 
assay was performed: TB was added at Vero cells as single dose [during adsorption (ADS) or after 422 
adsorption for the following 24 hrs (POST)] and as double doses (ADS+POST). Supernatants were 423 
subjected to standard plaque assay to evaluate viral production (upper panel). Data are means ± 424 
S.D. of 4 independent experiments, each performed in duplicate (*P < 0.05 vs. untreated sample). 425 
Cell lysates were analyzed by western blot with anti-HSV-1 and anti-gB antibodies; tubulin was 426 
used as loading control (lower panel). Densitometric analysis of gB levels is shown in the graph 427 
under the representative western blot and data are the means ± S.D. of three independent 428 
experiments performed.  *P<0.05 vs untreated cells. 429 
Figure 3 TB inhibits HSV-1 cell to cell spread. Vero cells were seeded in 96 wells, infected with 430 
HSV-1 (0.1 m.o.i.) and treated or no with TB during and after viral adsorption. 10 g/ml anti-HSV-431 
1 antibody (α HSV-1) were added for 24 hrs p.i.. Foci of infection were visualized by 432 
immunostaining with mouse anti-gB and IRDye 800CW goat anti-mouse antibodies. A 433 
representative image of one of the three experiments is shown (upper panel). The relative 434 
fluorescence intensity was detected with LI-COR Odyssey Infrared Imaging System, quantified by 435 
using LI-COR Image Studio Software and reported in the graph as % viral titer inhibition (lower 436 
panel). **P<0.01; ***P<0.001. 437 
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Figure 4 TB inhibits HSV-1 attachment to the host cells.  (A) In the attachment assay, Vero cells 438 
were infected with a combination of HSV-1 plus TB and inoculated cultures were kept for 1 hr at 4 439 
°C to allow virus attachment but not entry. Then, plaque reduction assay was performed. In the 440 
entry assay, cells were infected and kept at 4 °C for 1 hr to allow virus attachment; after wash, TB 441 
was added to the cells and the cultures were incubated for 1 hr at 37 °C to allow the HSV-1 442 
penetration. After a single wash with PBS pH 3 to remove eventually attached virus particles from 443 
the cell surface, cells were subjected to a plaque reduction assay. Viral titers, expressed as pfu/ml in 444 
the graph, are the means ± S.D. of 3 independent experiments, each performed in duplicate. **P < 445 
0.01 vs. untreated samples. Plaques stained with crystal violet are one representative experiment of 446 
the three performed. (B) Vero cells were pretreated with the peptide for 3 hrs at 37 °C before HSV-447 
1 infection. Conditioned medium samples were collected 24 hrs after infection and subjected to 448 
standard plaque assay. Data are means ± S.D. of 4 experiments, each performed in duplicate.  449 
Figure 5 TB exerts a virucidal effect. (A) HSV-1 (1 m.o.i.) was preincubated with TB at 37 °C for 450 
1 hr and the mixture was used to infect Vero cells for 24 hrs. Infected cellular monolayers were 451 
used for western blotting assay, which was performed by using an HSV-1 antibody; supernatants 452 
were collected and their viral content was quantified as PFU/ml by standard plaque assay, as 453 
reported under western blot image. (B) HSV-1 (20 m.o.i.) was preincubated with TB at 37 °C for 1 454 
hr and the mixture was diluted 20 fold (to obtain 1 m.o.i.) before infection. Standard plaque assay 455 
was performed. Data are means ± S.D. of 4 experiments, each performed in duplicate. **P < 0.01 456 
vs. untreated cells. 457 
Figure 6 TB disrupts the HSV-1 envelope. (A) TB or TA peptides were incubated with HSV-1 458 
(1x10
6
 pfu) virions for 1 hr at 37 °C as described in Methods. The morphology of viral particles 459 
was analyzed by TEM and compared with that of the untreated ones. Images were saved at 460 
x130,000 magnification; (B) HSV-1 (5x10
6
 pfu) were incubated with TB as described before. 461 
Images were saved at x180,000 magnification. Images are representative of results obtained from 462 
duplicates of two independent experiments. Helical wheels projections of TB and TA are also 463 
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shown (green, yellow and orange symbols refer to non polar, polar uncharged and basic residues, 464 
respectively). 465 
Figure 7 (A) Cytotoxic (CC50) and (B) antiviral effect of TB on human cells. (A) Confluent 466 
monolayers of Hela S3 and HEK-293 cells were incubated with increasing concentration of TB for 467 
24 hrs and cell proliferation was determined by MTT assay. The 50% cytotoxic concentration 468 
(CC50) of TB was calculated by regression analysis of the dose–response curve. (B) 20 µg/ml TB 469 
was added to HeLa S3 and HEK-293 cells during HSV-1 adsorption (ADS) or after viral adsorption 470 
for the following 24 hrs (POST).  HSV-1 was also pre-incubated with 20 µg/ml TB at 37 °C and the 471 
mixture was used to infect human cells for 24 hrs (TB/HSV-1 37°C). Supernatants were subjected 472 
to standard plaque assay to evaluate viral production. Data are means ± S.D. of 3 independent 473 
experiments, each performed in duplicate (*P < 0.05 vs. untreated sample).  474 
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